Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Type II RAF kinase inhibitors
US9358231B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9358231-B2 |
| Application number | US-201414552229-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 24, 2014 |
| Priority date | Dec 29, 2009 |
| Publication date | Jun 7, 2016 |
| Grant date | Jun 7, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
First claim
Opening claim text (preview).
What is claimed: 1. A method of treating lymphoma in a subject comprising administering to the subject a compound of formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
containing further heterocyclic rings · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9358231B2 cover?
- The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc, Univ Miami
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).